Variability in stone composition and metabolic correlation between kidneys in patients with bilateral nephrolithiasis by Rivera, Marcelino E. et al.
Variability in Stone Composition and Metabolic Correlation 
Between Kidneys in Patients with Bilateral Nephrolithiasis
Marcelino E. Rivera1, Charles U. Nottingham1, Michael S. Borofsky2, Suzanne M. Kissel3, 
Viraj Maniar4, Casey A. Dauw5, Nadya E. York6, Amy E. Krambeck1, James E. Lingeman1
1Department of Urology, Indiana University Health at Methodist Hospital
2Department of Urology, University of Minnesota
3Division of Urology, University of Utah School of Medicine
4Department of Urology, Medical College of Wisconsin
5Department of Urology, University of Michigan Health Systems
6Department of Urology, Auckland City Hospital
Abstract
Introduction: To evaluate the clinical significance of discordant stone analyses in patients 
undergoing bilateral ureteroscopy.
Methods: A retrospective chart review was performed for all patients undergoing stone 
extraction with bilateral ureteroscopy at our institution in an aim to identify patients who had 
bilateral stone analysis and 24-hour urine chemistry data available. Stones were then classified 
based upon the dominant present (>50%). Twenty-four hour urinalysis results were reviewed and 
statistical analysis performed comparing discordant and concordant patient populations, assessing 
significant differences that would potentially influence clinical management.
Results: We identified 79 patients (158 renal units) who had bilateral stones removed at the time 
of ureteroscopy. The majority of stones were classified as calcium oxalate (CaOx) (60.1%) 
followed by calcium phosphate (CaP) (27.8%), brushite (5.1%), uric acid (UA) (4.4%) and cystine 
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(2.5%). Discrepancies in stone classifications were present 24% of the time. Evaluation of 24-hour 
urinalysis results demonstrated that patients with CaOx:CaP stone discordance compared to 
CaOx:CaOx concordant stone formers were more likely to have an elevated pH (p=0.02) and 
lower uric acid supersaturation (p=0.01).
Conclusions: Discrepancies in stone mineral content are common in patients with bilateral 
stone disease. A single stone analysis from one side in the setting of bilateral stone disease is 
insufficient for management of patients with bilateral renal stones, and may lead to 
mismanagement when this misrepresented information is utilized in addition to 24-hour urinalysis 
results. At least one stone analysis should be performed from both sides during a bilateral stone 
extraction procedure.
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Introduction:
The current American Urological Association (AUA) guidelines recommend that stones be 
analyzed at least once when available.[1] There are no guidelines, however, discussing 
recommendations in obtaining a stone analysis when a bilateral stone procedure is 
performed. Furthermore, a recent review completed by the American College of Physicians 
(ACP) concluded that the current clinical trial evidence is insufficient to conclude that 
assessing stone composition, blood chemistry, or urine chemistry before or during 
pharmacologic or dietary management successfully prevents future stone events.[2] Despite 
the ACP conclusions, stone analysis and urine chemistries remain the cornerstone 
evaluations in the management of patients with nephrolithiasis and are recommended by the 
AUA.[3], [4]
To date, there is a limited amount of data surrounding discordant stone analysis when 
performing a simultaneous bilateral stone procedure.[4], [5] Stone analysis results as well as 
chemistries are utilized for the medical management of stone disease and could possibly be 
misrepresented if conflicting stone analysis results were present. The primary aim of this 
study was to review a cohort of bilateral stone forming patients in a prospectively collected 
ureteroscopy database to assess the prevalence of concordant and discordant stone 
compositions formed among renal units. Evaluations of both concordant and discordant 
patients who completed 24-hour urinalysis were performed to determine if there were 
significant differences between the two groups.
Patients and Methods:
A prospectively collected IRB-approved ureteroscopy database was utilized and coupled 
with a chart review for patients undergoing synchronous bilateral ureteroscopy from 2013 to 
2016 by a single surgeon (JEL) at a single hospital. All stones collected during the procedure 
were sent for analysis separately based on renal unit laterality. The stones were analyzed at a 
single stone analysis laboratory using all three of the following techniques for each test: 
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optical analysis, chemical analysis and Fourier transform infrared spectroscopy (Beck 
Analytical Laboratory, Indianapolis IN).
Stone composition per renal unit was classified by the dominant mineral present greater than 
fifty per cent. Stone compositions were identified as calcium oxalate (monohydrate or 
dihydrate) (CaOx), calcium phosphate (CaP), brushite, uric acid (UA), and cystine. An 
exception was made when brushite was present at any level. The renal unit was then 
classified as a brushite stone former.
Manual chart review was then completed for 24-hour urine study results (LithoLink, 
Labcorp). The study analyzed was the first 24-hour urine study completed for each patient, 
which at our institution is completed before the onset of medical stone management, and 
therefore represents the unaffected renal function. In first-time stone forming patients, this 
typically occurred after surgical treatment of the initial stone event, as is our routine 
practice. In patients whom we had previously treated for stone disease surgically, we 
included data from stone analysis obtained from the ureteroscopy during the study period 
(2013-2016) only. In these patients, we included the first 24-hour urine study obtained by the 
patient, which typically was obtained occurred the patient’s first stone event, and therefore 
may have been up to several years prior to the study period. This represented the initial 24-
hour urine study for the patient prior to intervention with any medical stone management.
Statistical analysis utilizing Student’s t-test was performed evaluating differences in means 
comparing discordant and concordant patient populations, assessing significant differences 
in urine chemistries that would influence clinical management. All analyses were performed 
using IBM SPSS software, version 25 (Armonk, NY) with a significance level of <0.05.
Results:
We identified 79 patients (158 renal units) who had bilateral stones removed at the time of 
ureteroscopy. The majority of stones were classified as calcium oxalate (CaOx) (60.1%) 
followed by CaP (27.8%), brushite (5.1%), uric acid (UA) (4.4%) and cystine (2.5%). 
Discrepancies in stone classifications between sides were present 24.1% of the time. Within 
the discordant stone results were the following analyses CaOx:CaP (63%), CaP: Brushite 
(32%), CaOx:UA (5%).
Among the 60 patients with concordant stone analyses, three patients (5%) had mixed UA 
and CaOx stones with all three having a predominance of UA. Also among patients with 
concordant stone analyses, 20 patients (33%) had both CaOx and CaP components. No 
patients of the concordant stones group had more than 2 types of stone present.
Among the 19 patients with discordant stone analyses, 17 patients (89%) had more than one 
type of stone present in the stone analysis from at least one side. Seventeen of these patients 
had a mixture of CaOx and CaP only in the stone on at least one side. Two (11%) patients 
among the discordant group had CaP and brushite only present in the stone on at least one 
side. Additionally, two of the discordant patients had 3 types of stone present on at least one 
side (both were a mixture of CaOx, CaP, and brushite). For both of these patients, the 
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brushite component was only present on one side. Ten (53%) patients among the discordant 
group had a pure stone on at least one side.
Overall, 62 patients (79%) within the cohort completed a 24-hour urinalysis (Table 1) with 
84% of the discordant stone formers completing a 24-hour urinalysis. Evaluation of 24-hour 
urinalysis results demonstrated striking differences between those with conflicting and 
similar stone analysis results. Those patients with CaOx:CaP stone discordance compared to 
CaOx:CaOx concordant stone formers (Table 2) were more likely to have an elevated pH 
(p=0.02) and lower UA supersaturation (p=0.01).
Discussion:
In a cohort of patients undergoing bilateral ureteroscopy, we identified a discordant stone 
analysis in 24% of cases. After evaluating the available 24-hour urinalysis results, we 
identified differences between CaOx:CaP and CaOx:CaOx stone formers with CaOx:CaP 
stone formers having an elevated pH and lower UA supersaturation than CaOx:CaOx stone 
formers. This difference in urinalysis results could lead a treating practitioner to patient 
mismanagement, both in the immediate post-operative management and long term if only a 
single stone analysis was performed for a given patient from a single side instead of both 
renal units. Specifically, practitioners not recognizing the presence of CaP stones may 
choose a treatment pathway that further alkalinizes the urine and potentially increases the 
risk CaP stones. Similarly, patients with an unrecognized UA stone component may not 
sufficiently recognize the importance of urinary alkalization.
Whether CaP stone or UA or other discordant stone disease is identified in a particular 
patient is due to several factors including the modality in which the stone is analyzed and the 
amount of stone submitted to the stone analysis laboratory. One of these is lab dependent 
while the other at the discretion of the treating urologist. While there exists no current “gold 
standard” for stone analysis, micro-CT is the most accurate but the lack of commercial 
availability makes other modalities including wet chemical analysis, infrared spectroscopy 
(FT-IR), x-ray diffraction more commonly used with variable success and determining 
components of mixed stones. Krambeck and colleagues assessed the accuracy of these 
variable stone composition analysis and found that in pure stones were more accurately 
analyzed than mixed stones, with significant discrepancies in mixed stone analysis results. 
Additionally, both the presence and absence of struvite in the stones was mischaracterized 
by multiple commercial labs. There was considerable variability with stones containing 
<50% apatite.[6] Given this potential for inaccuracies between labs and the finding of 24% 
of patients undergoing bilateral ureteroscopy having stone discordance between sides 
observed in the present study, the possibility of obtaining inaccurate information from a 
stone analysis can be high. Therefore, it would behoove urologists performing stone surgery 
to inquire as to the reputability of and techniques used by the analyzing facility so as to 
minimize the risk of receiving faulty information, in addition to ensuring that the bilateral 
stone specimens are sent for bilateral cases.
Literature regarding discordant stone formation is sparse. A retrospective review of fifty-
nine patients by Kadlec et al found a 25% discordant stone formation rate, which is very 
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similar to our findings.[4] They likewise found an increase in CaP in the discordant stone 
group. A larger series of 126 patients by Zhou et al found that a larger fraction (48%) of 
patients undergoing either bilateral PCNL or ureteroscopy had discordant stone analyses. 
While our investigation was solely in ureteroscopy patients, Kadlec’s and Zhou’s 
investigations included patients undergoing PCNL as well and notably, 20% of patients in 
the Kadlec study had a partial or complete staghorn. Not surprisingly, struvite stone disease 
was identified in several of these patients. In those studies, no investigation into the effects 
on 24-hour urinalysis was made.
Nephrolithiasis has increased in prevalence over the past two decades and while men 
continue to have a greater incidence of stone disease, women have been narrowing the 
gender gap.[7], [8] A recent investigation into the temporal changes in stone composition 
and risk factors by Xu et al demonstrated a significant increase in the number of females 
with calcium stone disease from 24% to 42% over a period 35 years. There is likewise 
evidence of an increasing prevalence of calcium phosphate stone disease,[8] presenting a 
potential management conundrum in the CaOx:CaP discordant stone former.
One potential mechanism for discordant stones between kidneys is prior treatment with 
shock wave lithotripsy. This treatment option has been demonstrated histologically to induce 
histologic changes in the local treatment area of the kidney including hemorrhage, direct 
tubular damage, and scar formation.[9] In fact, changes in stone composition have been 
reported following shock wave lithotripsy in patients who form cystine stones.[10] 
Reinstatler et al reported that male gender and increasing number of treatments with prior 
shock wave lithotripsy were independently associated with the formation of non-cystine 
stone composition in a multi-institutional cohort of 125 patients who form cystine stones. 
This is especially interesting given the unique mechanism of cystine stone formation, and 
would suggest that prior treatment to a region of a kidney may locally induce changes that 
affect the stone composition from that papilla.
Medical management of stone disease in the recurrent stone former can be a challenge for 
the treating stone surgeon. After fluid and dietary recommendations pharmacologic 
intervention plays an important role at stone prevention. For the hypercalciuric calcium 
stone former, thiazide diuretics have been demonstrated in clinical trials to lower stone risk 
by reducing urinary calcium and are recommended by the current AUA guidelines.[3], [11], 
[12]. The mechanism of stone reduction is poorly understood but is likely due to reduced 
urine calcium coupled with a reduction in supersaturation.[13] Potassium citrate is 
frequently paired with thiazide therapy, both to reduce the likelihood of hypokalemia and to 
reduce stone recurrence rates.[14], [15] However, most investigations into the efficacy of 
citrate therapy on stone prevention has been in CaOx stone formers.[15] While AUA 
guidelines recommend addition of citrate in stone formers who are hypocitriuric and for 
those with persistent disease despite optimal management,[3] concerns remain in particular 
recurrent stone formers with CaP predominant stones. Patients with bilateral stones having 
multiple components or with discordant stone types may present the urologist with an even 
greater challenge for medical management given potential differences in treatment 
considerations for different stone types.
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To date there is no randomized clinical evidence evaluating the effect of citrate therapy on 
CaP stone formation.[16], [17] In non-human studies of citrate therapy, potentially 
undesirable effects for CaP stone formation were noted including and increase in urinary pH 
and CaP supersaturation.[16] The concern for the managing urologist lies in the mechanism 
in which citrate decreases stone formation. While a portion of consumed citrate is filtered 
and complexes with calcium, thus decreasing stone formation, it also alkalinizes the urine 
via bicarbonate production after being metabolized by the liver and kidney.[18] This may 
result in a theoretical increase risk of CaP stone formation in particular in those with lower 
urine volumes and reduced urinary calcium.[18] A recent study by Dolzi et al[19] 
demonstrated that in hypercalciuric CaP stone formers, potassium citrate administration 
increased urine citrate and urine pH significantly compared to placebo and citric acid, but 
also increased brushite relative supersaturation ratio when measured with EQUIL2. While 
this study did not assess recurrent stone formation, it does leave the question of the relative 
risk and benefit of potassium citrate in these patients. To the urologist with a discordant 
CaOx:CaP stone former, the important information from a second stone analysis 
demonstrating predominant CaP stones would be particularly beneficial in recognizing the 
specific risk of worsening CaP supersaturation and potentially influence management 
depending on the provider’s assessment of the clinical picture. Particularly in the case of our 
present study where 63% of patients with discordant stones had a predominance of CaOx on 
one side versus CaP on the opposite side, the management would require consideration of 
both stone types when deciding whether a medication such as potassium citrate would be 
appropriate. Given the lack of knowledge about specific recurrent stone risk in these patients 
who take or do not take potassium citrate, further study would provide tremendous benefit.
Our investigation is not without limitations. Approximately 80% of our patients completed a 
24-hour urinalysis, which may not represent the urine chemistries of the entire cohort. 
Additionally, the small size of our cohort may not be generalizable to the population of stone 
formers regarding discordant stone analysis. Lastly, this was a retrospective review of a 
prospectively maintained database and thus is susceptible to selection bias.
Conclusions:
Discrepancies in stone classifications are common in patients with bilateral stone disease. 
When metabolic evaluation was performed in these patients there were significant 
differences between discordant and concordant groups, especially CaOx only and CaOx:CaP 
stone formers. Thus, a single stone analysis in the setting of bilateral stone disease is 
insufficient and may lead to mismanagement when it is utilized in addition to 24-hour 
urinalysis results. Consideration should be made to include at least one stone analysis from 
each renal unit on future guidelines.
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Table 1.


































CaOx:CaP(n=10) 2.06 (1.08) 8.49 
(3.13)








CaP:Brushite(n= 5) 1.27 (0.37) 8.60 
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CaOx:CaOx (n=33) 1.78 (0.82)
8.81 









CaP:CaP (n=9) 2.02 (0.61)
6.59 









UA:UA (n=3) 1.90 (1.13)
3.88 
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Table 2 –




Mean Urine Volume, L (SD) 1.78 (0.82) 2.06 (1.08) 0.39
Mean SS CaOx (SD) 8.81 (3.44) 8.49 (3.13) 0.47
Mean U Calcium, mg/day (SD) 233 (142) 281 (109) 0.79
Mean U Oxalate, mg/day (SD) 45.1 (19.8) 40.1 (19.4) 0.49
Mean U Citrate, mg/day (SD) 568 (287) 611 (262) 0.68
Mean SS CaP, (SD) 1.24 (1.01) 2.39 (1.77) 0.08
Mean 24 pH, (SD) 5.88 (0.45) 6.26 (0.44) 0.02
Mean SS Uric Acid, (SD) 1.19 (0.87) 0.579 (0.503) 0.01
Mean Uric Acid, g/day (SD) 0.612 (0.214) 0.658 (0.251) 0.58
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